ArticleBritish journal of cancer2003
Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.
Article in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number.Biology direct · 2022Review
- Adoptive Transfer of Dendritic Cells Expressing Fas Ligand Modulates Intestinal Inflammation in a Model of Inflammatory Bowel Disease.Journal of clinical & cellular immunology · 2016Article
- The Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy.International journal of tryptophan research : IJTR · 2016Review
- Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.Cancer immunology, immunotherapy : CII · 2015Article
- Dendritic cell cancer vaccines: from the bench to the bedside.Rambam Maimonides medical journal · 2014Article
- Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery.Journal of clinical immunology · 2011Article
- Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer.Current oncology reports · 2011Review
- Human FasL gene is a target of β-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions.PloS one · 2011Article
- Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.Journal of biomedicine & biotechnology · 2011Review
- Regulation of tumor immunity by tumor/dendritic cell fusions.Clinical & developmental immunology · 2010Review
- Clinical applications of a peptide-based vaccine for glioblastoma.Neurosurgery clinics of North America · 2010Review
- Fas ligand expression in lynch syndrome-associated colorectal tumours.Pathology oncology research : POR · 2009Article
- Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer.Familial cancer · 2009Article
- Requirement of inositol 1,4,5-trisphosphate receptors for tumor-mediated lymphocyte apoptosis.The Journal of biological chemistry · 2008Article
- Mechanisms involved in Korean mistletoe lectin-induced apoptosis of cancer cells.World journal of gastroenterology · 2007Article
- Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.World journal of gastroenterology · 2005Article
- Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes.BMC cancer · 2005Article
- Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells.World journal of gastroenterology · 2005Article
- Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.World journal of gastroenterology · 2005Article
- Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.World journal of gastroenterology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Many cancers express Fas ligand (FasL/CD95L) in vivo, and can kill lymphoid cells by Fas-mediated apoptosis in vitro. However, overexpression of recombinant FasL in murine tumour allografts revealed a potential antitumour effect of FasL, via recruitment of neutrophils. Transforming growth factor-beta1 (TGF-beta1) could inhibit these neutrophil-stimulatory effects of FasL. In the present study, we sought to determine directly whether FasL contributes to immune privilege or tumour rejection in human colon cancers in vivo, and whether TGF-beta1 regulates FasL function. Serial tumour sections were immunostained for FasL and TGF-beta1. Neutrophils and tumour infiltrating lymphocytes (TILs) were detected by immunohistochemistry for lactoferrin and CD45, respectively. Apoptotic TIL were identified by dual staining for TUNEL/CD45. FasL expression by nests of tumour cells was associated with a mean four-fold depletion of TILs (range 1.8-33-fold, n=16, P<0.001), together with a two-fold increase in TIL apoptosis (range 1.6-2.5-fold, n=14, P<0.001), relative to FasL-negative nests within the same tumours. The overall level of neutrophils present in all tumours examined was low (mean 0.3%, n=16), with FasL expression by tumour nests associated with a mean two-fold decrease in neutrophils, irrespective of TGF-beta1 expression. Together, our results suggest that tumour-expressed FasL is inhibitory rather than stimulatory towards antitumour immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.